Biosynthesis

Biosynthetic® Technologies Announces Dr. Matthew Kriech as New Chief Executive Officer

Retrieved on: 
Wednesday, January 24, 2024

INDIANAPOLIS, Jan. 24, 2024 /PRNewswire/ -- Biosynthetic Technologies, a leader in environmentally sustainable base oils, today announced the appointment of Dr. Matthew Kriech as its new Chief Executive Officer, effective immediately.

Key Points: 
  • INDIANAPOLIS, Jan. 24, 2024 /PRNewswire/ -- Biosynthetic Technologies, a leader in environmentally sustainable base oils, today announced the appointment of Dr. Matthew Kriech as its new Chief Executive Officer, effective immediately.
  • Dr. Kriech previously served as the Chief Operating Officer of Biosynthetic Technologies before becoming the President in 2023.
  • Dr. Kriech brings with him over 15 years of experience in the oleo and petrochemical industries.
  • Dr. Kriech aided in the acquisition and integration of Innoleo, the commodity Oleochemical arm of Biosynthetic Technologies in 2021.

Antheia Achieves Major Commercial Milestone

Retrieved on: 
Thursday, August 24, 2023

MENLO PARK, Calif., Aug. 24, 2023 /PRNewswire/ -- Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today announced the successful completion of its first 116,000L scale manufacturing run with a commercially-relevant fermentation titer for its debut product. The company also unveiled its initial product pipeline, which includes thebaine, oripavine, and scopolamine, all of which are KSMs (key starting materials) or APIs (active pharmaceutical ingredients) for producing critical medicines. Antheia's pipeline aligns with the U.S. Food and Drug Administration and the World Health Organization's Essential Medicines lists and the company's platform supports growing efforts to improve global access to essential medicines.

Key Points: 
  • Antheia was founded on the belief that synthetic biology can be leveraged to produce highly complex pharmaceutical molecules at commercial scale with greater efficiency than current approaches.
  • With Antheia, customers can gain greater control and visibility over their pharmaceutical ingredient supply chains," said Christina Smolke, PhD, CEO and co-founder at Antheia.
  • "It is exciting to see the convergence of our commercial progress with our mission to transform pharmaceutical supply chains for more equitable access to medicines."
  • Today's announcement demonstrates Antheia's strong scientific and commercial trajectory, and also signals how synthetic biology can – and will – deliver on its promise to revolutionize major industries.

TELA Bio Highlights Published Clinical Research from 2022 Showcasing Safety and Performance of Reinforced Biologic for Hernia Indications

Retrieved on: 
Thursday, March 16, 2023

(NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today highlights six studies published in 2022.

Key Points: 
  • (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today highlights six studies published in 2022.
  • It is estimated that over two million hernia repairs will be performed this year within the United States, Europe, and the United Kingdom.
  • Launched in June 2016, OviTex has been rigorously studied in the clinical setting since its commercialization.
  • * Clinical Outcomes of Open Abdominal Wall Reconstruction with the Use of a Polypropylene Reinforced Tissue Matrix: A Multicenter Retrospective Study.

Global mRNA Synthesis and Manufacturing Services Market Research Report 2022-2035: Growing Need for Outsourcing mRNA Synthesis and Manufacturing Services to Contract Manufacturers

Retrieved on: 
Sunday, January 22, 2023

The "mRNA Synthesis and Manufacturing Services Market (2nd Edition), 2022-2035" report features an extensive study of the current market landscape and future opportunity for the players involved in the synthesis and manufacturing of research- and GMP-grade mRNA for use in the development of therapeutics and vaccines.

Key Points: 
  • The "mRNA Synthesis and Manufacturing Services Market (2nd Edition), 2022-2035" report features an extensive study of the current market landscape and future opportunity for the players involved in the synthesis and manufacturing of research- and GMP-grade mRNA for use in the development of therapeutics and vaccines.
  • One of the key objectives of the report was to estimate the current opportunity and the future growth potential of the mRNA synthesis and contract manufacturing services market over the coming years.
  • Presently, more than 195 mRNA therapeutics / mRNA vaccines are under development or commercialized for the treatment of a variety of indications.
  • Specifically, in terms of type of product, the market is anticipated to be driven by contract manufacturing of mRNA vaccines.

Global mRNA Synthesis and Manufacturing Services Markets, 2022-2035: Market Landscape and Future Opportunity for the Players Involved in the Synthesis and Manufacturing of Research- and GMP-grade mRNA - ResearchAndMarkets.com

Retrieved on: 
Monday, January 16, 2023

The "mRNA Synthesis and Manufacturing Services Market (2nd Edition), 2022-2035" report features an extensive study of the current market landscape and future opportunity for the players involved in the synthesis and manufacturing of research- and GMP-grade mRNA for use in the development of therapeutics and vaccines.

Key Points: 
  • The "mRNA Synthesis and Manufacturing Services Market (2nd Edition), 2022-2035" report features an extensive study of the current market landscape and future opportunity for the players involved in the synthesis and manufacturing of research- and GMP-grade mRNA for use in the development of therapeutics and vaccines.
  • One of the key objectives of the report was to estimate the current opportunity and the future growth potential of the mRNA synthesis and contract manufacturing services market over the coming years.
  • Presently, more than 195 mRNA therapeutics / mRNA vaccines are under development or commercialized for the treatment of a variety of indications.
  • Specifically, in terms of type of product, the market is anticipated to be driven by contract manufacturing of mRNA vaccines.

Xinteza Unveils Disruptive Non-Cannabaceae Source for Cannabinoid Biosynthesis in Breakthrough Research Led by Prof. Asaph Aharoni at the Weizmann Institute of Science

Retrieved on: 
Thursday, August 11, 2022

The company's IP portfolio is based on a license signed with Yeda, the commercial arm of the Weizmann Institute of Science.

Key Points: 
  • The company's IP portfolio is based on a license signed with Yeda, the commercial arm of the Weizmann Institute of Science.
  • Biosynthesis technologies have the potential to revolutionize cultivation-and-extraction-based production methods of cannabinoid compounds for CPG and pharma.
  • Xinteza holds an exclusive license for both cannabinoids and psychoactives from the Weizmann Institute of Science with research led by Prof. Asaph Aharoni and is diligently building an unprecedented portfolio of dozens of related IP assets and patents.
  • Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science.

Global CBD Skin Care Market Size Anticipated To Reach $3.4 Billion By 2026, With A CAGR Of 24.80%

Retrieved on: 
Tuesday, December 21, 2021

A report from Allied Market Research projected that the global CBD skin care market size, which was valued at $633.6 million in 2018, is anticipated to reach $3,484.00 Million by 2026, with a CAGR of 24.80% during the forecast period.

Key Points: 
  • A report from Allied Market Research projected that the global CBD skin care market size, which was valued at $633.6 million in 2018, is anticipated to reach $3,484.00 Million by 2026, with a CAGR of 24.80% during the forecast period.
  • This trend is expected to gain traction among the global CBD skin care market players in few years."
  • North America is anticipated to dominate the CBD skin care market share, registering a CAGR of 24.3% during the forecast period.
  • The departmental stores distribution segment is anticipated to dominate the global CBD skin care market analysis, with a CAGR of 23.5% during the forecast period.

Global CBD Skin Care Market Size Anticipated To Reach $3.4 Billion By 2026, With A CAGR Of 24.80%

Retrieved on: 
Tuesday, December 21, 2021

A report from Allied Market Research projected that the global CBD skin care market size, which was valued at $633.6 million in 2018, is anticipated to reach $3,484.00 Million by 2026, with a CAGR of 24.80% during the forecast period.

Key Points: 
  • A report from Allied Market Research projected that the global CBD skin care market size, which was valued at $633.6 million in 2018, is anticipated to reach $3,484.00 Million by 2026, with a CAGR of 24.80% during the forecast period.
  • This trend is expected to gain traction among the global CBD skin care market players in few years."
  • North America is anticipated to dominate the CBD skin care market share, registering a CAGR of 24.3% during the forecast period.
  • The departmental stores distribution segment is anticipated to dominate the global CBD skin care market analysis, with a CAGR of 23.5% during the forecast period.